Notice: This company has been marked as potentially delisted and may not be actively trading. TF Financial (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock THRD vs. CVAC, TRVI, NUVB, BCYC, IMNM, DNTH, PHAR, GHRS, KALV, and QUREShould you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include CureVac (CVAC), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Immunome (IMNM), Dianthus Therapeutics (DNTH), Pharming Group (PHAR), GH Research (GHRS), KalVista Pharmaceuticals (KALV), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry. TF Financial vs. CureVac Trevi Therapeutics Nuvation Bio Bicycle Therapeutics Immunome Dianthus Therapeutics Pharming Group GH Research KalVista Pharmaceuticals uniQure TF Financial (NASDAQ:THRD) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings. Is THRD or CVAC more profitable? CureVac has a net margin of 20.72% compared to TF Financial's net margin of 0.00%. CureVac's return on equity of 21.98% beat TF Financial's return on equity.Company Net Margins Return on Equity Return on Assets TF FinancialN/A -9.31% -9.03% CureVac 20.72%21.98%15.72% Do analysts recommend THRD or CVAC? TF Financial presently has a consensus price target of $9.33, suggesting a potential upside of 168.97%. CureVac has a consensus price target of $10.00, suggesting a potential upside of 264.30%. Given CureVac's stronger consensus rating and higher possible upside, analysts plainly believe CureVac is more favorable than TF Financial.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TF Financial 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CureVac 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has higher earnings and valuation, THRD or CVAC? TF Financial has higher earnings, but lower revenue than CureVac. TF Financial is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTF FinancialN/AN/A-$30.82M-$0.62-5.60CureVac$543.28M1.13-$281.58M$0.554.99 Does the MarketBeat Community favor THRD or CVAC? TF Financial received 35 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 65.59% of users gave TF Financial an outperform vote while only 55.32% of users gave CureVac an outperform vote. CompanyUnderperformOutperformTF FinancialOutperform Votes6165.59% Underperform Votes3234.41% CureVacOutperform Votes2655.32% Underperform Votes2144.68% Does the media prefer THRD or CVAC? In the previous week, CureVac had 12 more articles in the media than TF Financial. MarketBeat recorded 15 mentions for CureVac and 3 mentions for TF Financial. CureVac's average media sentiment score of 0.57 beat TF Financial's score of 0.00 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TF Financial 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CureVac 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in THRD or CVAC? 94.0% of TF Financial shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.9% of TF Financial shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, THRD or CVAC? TF Financial has a beta of 2.66, meaning that its stock price is 166% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. SummaryCureVac beats TF Financial on 11 of the 17 factors compared between the two stocks. Remove Ads Get TF Financial News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricTF FinancialPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$156.36M$6.74B$5.54B$7.80BDividend YieldN/A2.81%5.35%4.05%P/E Ratio-5.607.1323.4718.58Price / SalesN/A200.24368.6387.66Price / CashN/A65.6738.1634.64Price / Book0.525.986.624.07Net Income-$30.82M$142.11M$3.20B$246.93M TF Financial Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDTF Financial1.4993 of 5 stars$3.47-1.1%$9.33+169.0%-62.8%$156.36MN/A-5.60N/AEarnings ReportCVACCureVac3.8184 of 5 stars$2.77-7.0%$10.00+261.0%-8.6%$620.15M$543.28M5.04880TRVITrevi Therapeutics3.6591 of 5 stars$6.29-3.2%$17.56+179.2%+82.3%$608.13MN/A-14.3020Short Interest ↑Gap DownHigh Trading VolumeNUVBNuvation Bio1.9646 of 5 stars$1.78-2.5%$8.75+393.0%-51.2%$601.16M$7.87M-0.8260BCYCBicycle Therapeutics1.8635 of 5 stars$8.49-5.4%$29.14+243.3%-65.9%$587.53M$35.28M-2.58240IMNMImmunome2.1133 of 5 stars$6.73-3.7%$25.50+278.9%-72.7%$585.18M$9.04M-0.8340Gap UpHigh Trading VolumeDNTHDianthus Therapeutics1.3498 of 5 stars$18.14-9.3%$54.33+199.5%-39.5%$582.75M$6.24M-7.2680PHARPharming Group2.1473 of 5 stars$8.48+2.0%$30.00+253.8%-21.8%$576.90M$297.20M-32.62280GHRSGH Research2.476 of 5 stars$11.03-0.3%$30.86+179.8%+3.5%$573.87MN/A-13.9610KALVKalVista Pharmaceuticals4.2184 of 5 stars$11.54-3.3%$24.83+115.2%-2.7%$573.72MN/A-3.17100QUREuniQure2.5205 of 5 stars$10.60-15.0%$38.89+266.9%+103.8%$573.22M$27.12M-2.14500Analyst ForecastHigh Trading Volume Remove Ads Related Companies and Tools Related Companies CureVac Competitors Trevi Therapeutics Competitors Nuvation Bio Competitors Bicycle Therapeutics Competitors Immunome Competitors Dianthus Therapeutics Competitors Pharming Group Competitors GH Research Competitors KalVista Pharmaceuticals Competitors uniQure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THRD) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TF Financial Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share TF Financial With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
